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ABSTRACT
Bronchial asthma is a common inflammatory disease caused by a combination of genetic and environmental
factors. To discover the genes and cellular pathways underlying asthma, a large number of genetic studies
have been conducted. Genome-wide association studies (GWAS), which comprehensively assess genes re-
lated to multifactorial diseases and drug reactivity, have enhanced understanding of human diseases. From
2007, GWAS of susceptibility to asthma in Caucasian, Mexican, and African-ancestry populations have been
conducted and several susceptible loci were identified. Recently, much larger consortium-based GWAS analy-
ses of collaborative samples with adequate statistical power were performed, and the implicated genes sug-
gested a role for communication of epithelial damage to the adaptive immune system and activation of airway
inflammation. Furthermore, GWAS identified candidate loci associated with natural variations in lung function,
blood eosinophilia and eosinophilic esophagitis, which is inflammation of the esophagus with abnormal infiltra-
tion of eosinophils in an allergic reaction. Comparing GWAS in asthma and these clinical phenotypes might
help to clarify the mechanisms underlying asthma. Pharmacogenomics analyses using GWAS regarding ge-
netic factors related to the effectiveness of inhaled corticosteroid (ICS) therapy and inhaled beta2-adrenergic
agonists are ongoing now. Although a more complete collection of associated genes and pathways is needed,
biologic insights revealed by GWAS provide valuable insights into the pathophysiology of asthma and contrib-
ute to the development of better treatment and preventive strategies.
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INTRODUCTION
Bronchial asthma is a complex disease caused by a
combination of genetic and environmental factors.1,2
Human genome research has been conducted to con-
tribute to the establishment of personalized medicine,
which will provide more appropriate therapies to indi-
vidual patients. Genetic information is encoded by the
four DNA bases, adenine (A), cytosine (C), guanine
(G) and thymine (T), and the genetic information in-
cludes regions that vary among different individuals.
Human genetic variants are referred to as either com-
mon or rare, and common variants are also called
polymorphisms, defined as variants with a minor al-
lele frequency of at least 1% in the population.3 Ge-
netic variants are also divided into single nucleotide
variants and structural variants, including insertion-
deletion variants, block substitution, inversion vari-
ants and copy number variants.3 Among the various
different types of genetic polymorphisms, single nu-
cleotide polymorphisms (SNPs) are the most preva-
lent class of genetic variations among individuals.3
There is one SNP for every 1000 base pairs and there
are about 10 million SNPs in the entire human
genome. It is thought that SNPs found around a gene
may cause variations in the timing, amount, and func-
tion of the protein product and influence human
health and diseases.
The international HapMap project (http:hapmap.
ncbi.nlm.nih.gov) started from 2002 to develop a
public resource that will help researchers to find
genes associated with human diseases and individual
responses to pharmacological agents.4 The HapMap
project focuses only on common SNPs with minor al-
lele frequencies >1% in the population and defines
these patterns across the entire genome. The discov-
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Table　1　Asthma susceptibility loci identifi ed by GWAS
Year Region Reported genes
Strongest 
SNP
RAF in 
control P-value
OR or beta-
coefficient 
(95% CI)
GWAS 
Platform
SNPs 
passing 
QC
Reference
1 2007 17q12 ORMDL3 rs7216389 0.52  9 × 10-11 1.45 (1.17-1.81) Illumina 307,328  9
2 2009 5q12.1 PDE4D rs1588265 0.29 3 × 10-8 1.18 (1.08-1.30) Illumina 518,230 18
3 2009 NS NS NS NS NS NS Illumina -644,503 19
4 2010 1q31.3 DENND1B, 
CRB1
rs2786098 0.85  2 × 10-13 1.18 (1.08-1.30) Illumina -550,000 21
5 2010 5q31.1 RAD50 rs2244012 0.21 3 × 10-7 1.64 (1.36-1.97) Illumina 292,443 23
15q21.2 SCG3 rs17525472 NR 2 × 10-6 NR
20p13 KIAA1271 rs4815617 NR 8 × 10-6 NR
6 2010 6p21.32 HLA-DQ rs9273349 0.58  7 × 10-14 1.18 (1.13-1.24) Illumina 582,892 25
9p24.1 IL33 rs1342326 0.16  9 × 10-10 1.20 (1.13-1.28)
2q12.1 IL18R1 rs3771166 0.62 3 × 10-9 1.15 (1.10-1.20)
15q22.33 SMAD3 rs744910 0.49 4 × 10-9 1.12 (1.09-1.16)
17q21.1 GSDMA rs3894194 0.45 5 × 10-9 1.17 (1.11-1.23)
22q12.3 IL2RB rs2284033 0.56 1 × 10-8 1.12 (1.08-1.16)
15q22.2 RORA rs11071559 0.86 1 × 10-7 1.18 (1.11-1.25)
17q12 GSDMB rs2305480 0.55 1 × 10-7 1.18 (1.11-1.23)
5q31.1 IL13 rs1295686 0.2 1 × 10-7 1.15 (1.09-1.20)
5q31.1 SLC22A5 rs2073643 0.45 2 × 10-7 1.11 (1.06-1.15)
RAF, risk allele frequency; OR, odds ratio; QC, quality control; NS, not signifi cant; NR, not reported.
ery of the haplotype structure of the human genome
implied that a limited set of 1,000,000 SNPs could
capture -90% of the genetic variation in the popula-
tion.5 Genotyping arrays have been developed with
reference to linkage disequilibrium, which can now
assay up to -2 million variants. The data from the Hap-
Map project and the development of dense genotyp-
ing chips have enabled us to conduct GWAS on a
large number of samples.
To date, large numbers of genetic association stud-
ies using the candidate gene approach for asthma and
asthma-related phenotypes have been conducted in
different populations.6 However, some of the studies
had methodological issues such as lack of power and
replication, insufficient polymorphism coverage of a
gene, and small sample sizes.7 From 2007, GWAS of
asthma were started in multiple research groups. Re-
cently, consortia were formed and the results from
GWAS can be evaluated in a meta-analysis, that com-
bines the results of multiple studies to improve the
power for detecting associations. Systemic, well-
powered, genome-wide surveys using GWAS have ex-
plored the relationship between SNPs and disease
susceptibility.8 This review focuses on GWAS of
asthma and asthma-related phenotypes. We also dis-
cuss the road ahead for asthma genetics.
GWAS OF ASTHMA
Several GWAS of asthma have been conducted, and
the Table 1 summarizes the findings.
The first GWAS of asthma showed that single nu-
cleotide polymorphisms (SNPs) on the chromosome
17q21.1 locus contributed to the risk of childhood
asthma.9 Genetic variants of the region were strongly
associated in cis with transcript levels of ORMDL3 in
Epstein-Barr virus (EBV)-transformed lymphoblas-
toid cell lines from children with asthma. The finding
has been successfully replicated in diverse ethnic
populations; however, it appears that the region is as-
sociated with childhood, but not adult-onset,
asthma.10-15 We confirmed a significant association
between susceptibility to childhood atopic asthma
and the polymorphism regulating ORMDL3 expres-
sion in a Japanese population, and also found that the
expression level of ORMDL3 was strongly induced
for 24 h by stimulation with poly (I:C), which mimics
the state of viral infection.10 Viral respiratory infec-
tions are a common trigger of childhood asthma. Up
to 80% of exacerbations of asthma in children and
about half of such episodes in adults are caused by vi-
ral infections.16 Another twin study has shown that
host-related differences in genetic makeup cause dif-
ferent individuals to develop asthma at different
ages.17 Further analysis of the causes for variation in
the age at onset of the disease might lead to better
understanding of the pathophysiology of asthma.
Himes et al. conducted GWAS of asthma with 359
cases from the Childhood Asthma Management Pro-
gram (CAMP) and 846 genetically matched controls
from the Illumina ICONdb public resource.18 The
study found strong associations between asthma and
SNPs in phosphodiesterase 4D, cAMP-specific (phos-
phodiesterase E3 dunce homolog, Drosophila )
(PDE4D) as an asthma susceptibility gene on chro-
GWAS of Asthma
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Fig.　1　Asthma is a heterogeneous disease with various 
clinical phenotypes.
Onset of age (childhood or adult)
Seasonal or perennial
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Lower pulmonary function
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With or without blood eosinophilia
Patients with combined asthma and COPD
Smoking and passive smoking
Bronchial Asthma
mosome 5q12. The results were replicated in two
white and Hispanic populations; however, the original
findings were not replicated in three black popula-
tions. Interestingly, PDE4D is a regulator of airway
smooth-muscle contractility, and PDE4 inhibitors
have been developed as medications for asthma.
Mathias et al. reported a GWAS for asthma in
populations of African descent.19 More than 640,000
SNPs were tested for association with asthma using
two independent populations, an African American
case-control group from Baltimore-Washington, DC
(n = 935), and 163 African Caribbean families from
Barbados (n = 929). The study found three potential
asthma genes: α-1B-adrenergic receptor (ADRA1B) on
chromosome 5q33, prion-related protein (PRNP) on
chromosome 20pter-p12, and DPP10 on chromosome
2q12.3-q14.2. However, the associations were not rep-
licated in two white populations. Replication study is
important to determine generalizability and to assure
that results are valid and reliable. Sometimes, replica-
tion of results is achieved at the level of the gene but
not of a specific SNP, but replication can encounter
several types of failure. The above reports suggested
the difficulties of genetic studies on ethnically and ra-
cially diverse samples by using genotyping platforms
designed to assess variants common in Caucasians.
Commercially available chips were constructed using
SNPs identified in European-derived samples and the
density of SNP sets on these chips does not provide
adequate coverage.20 Development of new technolo-
gies that more accurately capture the genetic diver-
sity in non-European populations is awaited.20
Sleiman et al. conducted GWAS involving child-
hood asthma using samples from persons of Euro-
pean ancestry.21 The sample included 793 North
American children of European ancestry with persis-
tent asthma who required daily inhaled glucocorti-
coid therapy and 1988 matched controls. A replication
study was performed in an independent cohort of 917
persons of European ancestry who had asthma and
1546 matched controls. They found a novel asthma-
susceptible locus on chromosome 1q31, which con-
tains two genes, CRB1 and DENND1B. CRB1 en-
codes a transmembrane protein that is involved in the
morphogenesis and maintenance of the retinal epithe-
lium. DENND1B is expressed in dendritic cells and
activates T cells; however the function of DENND1B
remains unknown. The study also replicated the asso-
ciation between asthma and SNPs at the previously
reported locus on 17q21.
In asthma, different clinical phenotypes are recog-
nized. Approximately 5% of patients have severe
asthma that is difficult to control with maximal in-
haler therapy.22 To identify genes that are associated
with the severity of the disease might allow targeting
of preventive treatments. Li et al. focused on the
pathogenesis of the disease and conducted a GWAS
on a population of patients with severe or difficult-to-
treat asthma.23 Association with asthma was analyzed
using 292,443 SNPs in cases from The Epidemiology
and Natural History of Asthma: Outcomes and Treat-
ment Regimens (TENOR) population and Illumina
general population control subjects. Imputation was
also performed in identified candidate loci. Imputa-
tion is a method that can deduce the allelic states at
polymorphic sites not genotyped from the surround-
ing SNP information based on linkage disequilibrium
and likelihood estimates.24 Their study finally identi-
fied two loci associated with asthma, the RAD50-IL13
region on chromosome 5q31.1 and HLA-DRDQ re-
gion on chromosome 6p21.3. These findings imply
the important role of Th2 cytokine and antigen pres-
entation genes in asthma.
Large sample sizes are required to ensure suffi-
cient statistical power, and collaborative studies on
samples from a large number of cohorts have pro-
vided new insights about the genetic bases of com-
mon diseases. A recent large-scale, consortium-based
GWAS of asthma was conducted with 10,365 cases
and 16,110 controls. The study identified six candi-
date loci that contained IL1RL1IL18R1, HLA-DQ,
IL33, SMAD3, ORMDL3GSDMB and IL2RB.25 The
ligand for IL1RL1 is IL-33, which has been shown to
be important in Th2-associated disease models. The
house dust mite allergen has cysteine protease activ-
ity and is usually contaminated with low levels of
lipopolysaccharide (LPS).26 Cysteine protease- and
or LPS-containing allergens can activate lung epithe-
lial cells to produce TSLP and IL-33, which initiate
Th2 immune responses by acting on basophils and
dendritic cells.27 These act as antigen-presenting cells
to drive Th2 cell differentiation, and IL-2 produced by
Th2 cells can self-amplify the differentiation proc-
ess.27 The findings of GWAS imply that genes which
play a role for communication of epithelial damage to
the adaptive immune system and activation of airway
inflammation are associated with susceptibility to
asthma.
GWAS OF ASTHMA-RELATED PHENOTYPES
Asthma is a heterogeneous disease with various clini-
cal phenotypes (Fig. 1). To date, GWAS have identi-
fied candidate loci associated with natural variations
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in lung function, a number of blood eosinophilias and
an eosinophilic disorder. Lower pulmonary function
and persistent eosinophilia are features of severe
asthma. Comparing the results of GWAS in asthma
and in these clinical phenotypes might help to clarify
the mechanisms underlying asthma.
Pulmonary function measures are heritable traits
that reflect respiratory health and predict morbidity
and mortality. GWAS for lung function were reported
using cross-sectional spirometric measurements in
healthy individuals. Hancock conducted meta-
analyzed GWAS for forced expiratory volume in the
first second (FEV1) and its ratio to forced vital capac-
ity (FEV1FVC) using 20,890 participants of Euro-
pean ancestry from four CHARGE Consortium stud-
ies: Atherosclerosis Risk in Communities, the Cardio-
vascular Health Study, Framingham Heart Study and
Rotterdam Study.28 Eight loci associated with FEV1
FVC (HHIP, GPR126, ADAM19, AGER-PPT2,
FAM13A, PTCH1, PID1 and HTR4) and one locus as-
sociated with FEV1 (INTS12-GSTCD-NPNT) were
identified at the level of or with near genome-wide
significance (P < 5 × 10-8) in the dataset. Repapi et al.
investigated genome-wide association with FEV1 and
FEV1FVC in the SpiroMeta consortium using 20,288
individuals of European ancestry. They further per-
formed a meta-analysis of top signals with data from
direct genotyping in up to 32,184 individuals and in
silico summary association data relating to a further
22,092 individuals.29 The previously reported locus at
4q31 was confirmed, and associations with FEV1 or
FEV1FVC and common variants at five additional
loci were identified: 2q35 in TNS1 (P = 1.11 × 10-12),
4q24 in GSTCD (2.18 × 10-23), 5q33 in HTR4 (P =
4.29 × 10-9), 6p21 in AGER (P = 3.07 × 10-15) and 15q
23 in THSD4 (P = 7.24 × 10-15). Reduction of FEV1
FVC is a characteristic of obstructive lung diseases
such as asthma, and natural variations in lung func-
tion may have implications for asthma. Further stud-
ies are necessary to clarify the relationship between
genetic determinants of lung function and susceptibil-
ity to asthma as well as its severity.
Eosinophils, a marker of airway inflammation in
asthma, are found in increased numbers in the pe-
ripheral blood and sputum, usually in relation to the
severity of asthma. A recent GWAS identified five loci
that influence blood eosinophilia and examined the
relation of genetic variants associated with blood
eosinophilia in asthma.30 SNPs in four eosinophilia-
related genes (IL1RL1, IL33, WDR36, and MYB)
showed evidence of association with asthma. The sus-
ceptible region on chromosome 5q22 includes two
genes, TSLP and WDR36. Eosinophilic esophagitis is
characterized by inflammation and a large number of
eosinophils in the esophagus. Rothenberg et al. re-
ported association of eosinophilic esophagitis with
variants at chromosome 5q22 encompassing thymic
stromal lymphopoietin (TSLP) and WDR36.31 In the
study, TSLP was found to be overexpressed in
esophageal biopsied tissues from individuals with
eosinophilic esophagitis compared with unaffected in-
dividuals. Although further investigation is required
to determine the functions of the related variants in
eosinophils, current studies imply that this TSLP
WDR36 locus contains a genetic factor involved in
eosinophilic diseases. TSLP initiates Th-2-mediated
immune responses and plays crucial roles in allergic
inflammation.32 Current annotation implies that TSLP
is the most plausible susceptibility gene in this locus.
Since a correlation between clinical asthma severity
and the degree of airway eosinophilia has been re-
ported, further investigations are required to examine
whether genetic variants involved in eosinophlic dis-
eases are associated with the severity of the disease.
PHARMACOGENETICS OF ASTHMA
It is known that the reactions to therapeutic agents
differ enormously among individual patients. Pharma-
cogenetics is the study of genetic influences on inter-
individual variability in responses to drugs. If we can
find relations of genetic variations with the effective-
ness andor risks of side effects of drugs, it will pro-
vide the useful information to improve medical care.
Recent GWAS have identified an association between
an IL-28B polymorphism and the response to pe-
gylated interferon-alpha and ribavirin therapy for
chronic hepatitis C.33,34 These studies help identify
patients for whom therapy is likely to be successful
and highlight IFN-lambda signaling as a potential tar-
get for novel antiviral drug development. Pharmaco-
genetic studies in patients with asthma have been
conducted using the candidate gene approach. Exam-
ined candidate genes were selected based on our un-
derstanding of drug pathways.35 Pharmacogenomic
analyses using GWAS have been performed to eluci-
date genetic factors related to the effectiveness of in-
haled corticosteroid (ICS) therapy and inhaled beta2-
adrenergic agonists. The rapid progress in the phar-
macogenetics of asthma will help to define patient
populations who are most likely to benefit from vari-
ous treatments, and lead to development of new
therapeutic modalities.
FUTURE PERSPECTIVES
Recent GWAS have provided many valuable insights
into the genetic components of human diseases.
However they have elucidated relatively little of the
heritability of complex diseases.36 It has been recog-
nized that approximately 60% of SNPs in the human
genome have minor allele frequencies of less than 5%,
and the chips currently used in GWAS contain rela-
tively few rare SNPs in the coding and promoter re-
gions of their SNP genotyping panels. Rare large-
effect mutations are now recognized as causes of
many different common medical conditions.37 The
1000 Genomes Project aims to find essentially all vari-
GWAS of Asthma
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ants with frequencies >1% across the genome and
>0.1% in protein-coding regions.38 The project ex-
pands the catalog of variations for the next generation
of GWAS, and it will identify nearly all variants that
exist with any appreciable frequency in human popu-
lations. Next-generation high-throughput sequencing
technologies might contribute to identification of vari-
ants involved in the etiologies of common diseases.
Complementary approaches such as exon-based or
genome-wide sequencing with sufficient sample sizes
should yield important new genetic insights into com-
mon diseases.39 In addition, intensive functional stud-
ies will be required to characterize the genes and
pathways, and to construct animal models that mimic
human physiology. Though our current knowledge is
far from comprehensive, we should remember, as
Lander recently wrote, “Importantly, complete expla-
nation of a disease is not required for progress.”5
CONCLUSION
The HapMap, a catalogue of human genetic vari-
ations and a haplotype map, together with progress of
high-throughput genotyping technology have en-
abled GWAS with large numbers of samples. Collabo-
rative genetic studies using very large population
samples have provided valuable insights into the
pathophysiology of asthma. Further studies to eluci-
date the functional links between associated variants
and phenotypic traits are important for the improve-
ment of our knowledge of asthma.
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